Akebia Therapeutics Signs Contract to Expand Vafseo Access for Patients on Dialysis; Shares Rise

MT Newswires Live10-22

Akebia Therapeutics (AKBA) said Tuesday it signed a commercial contract with a kidney care services provider to help expand access to Vafseo, or vadadustat, for patients on dialysis.

Vafseo is indicated to treat anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, the company said.

Under the multiyear contract, physicians will be able to prescribe Vafseo to patients on dialysis as deemed clinically appropriate. Akebia said it expects Vafseo to be available in the US in January 2025.

The company's shares were up nearly 6% in recent trading.

Price: 1.45, Change: +0.08, Percent Change: +5.84

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2477351663?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-22 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477351663","market":"sg","top_or_hot":-1,"title":"Akebia Therapeutics Signs Contract to Expand Vafseo Access for Patients on Dialysis; Shares Rise","media":"MT Newswires Live","content":"<html><body><p> Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AKBA) said Tuesday it signed a commercial contract with a kidney care services provider to help expand access to Vafseo, or vadadustat, for patients on dialysis.</p><p>Vafseo is indicated to treat anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, the company said.</p><p>Under the multiyear contract, physicians will be able to prescribe Vafseo to patients on dialysis as deemed clinically appropriate. Akebia said it expects Vafseo to be available in the US in January 2025.</p><p>The company's shares were up nearly 6% in recent trading.</p><p>Price: 1.45, Change: +0.08, Percent Change: +5.84</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akebia Therapeutics Signs Contract to Expand Vafseo Access for Patients on Dialysis; Shares Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkebia Therapeutics Signs Contract to Expand Vafseo Access for Patients on Dialysis; Shares Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-22 22:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Akebia Therapeutics (AKBA) said Tuesday it signed a commercial contract with a kidney care services provider to help expand access to Vafseo, or vadadustat, for patients on dialysis.Vafseo is ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKBA","symbol_name":"Akebia Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2477351663","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477351663","pubTimestamp":1729607699,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Akebia Therapeutics  said Tuesday it signed a commercial contract with a kidney care services provider to help expand access to Vafseo, or vadadustat, for patients on dialysis.Vafseo is indicated to treat anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, the company said.Under the multiyear contract, physicians will be able to prescribe Vafseo to patients on dialysis as deemed clinically appropriate. Akebia said it expects Vafseo to be available in the US in January 2025.The company's shares were up nearly 6% in recent trading.Price: 1.45, Change: +0.08, Percent Change: +5.84","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AKBA":"Akebia Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Akebia Therapeutics签署合同，扩大透析患者使用Vafseo的机会；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKBA":1},"content_text":"Akebia Therapeutics (AKBA) said Tuesday it signed a commercial contract with a kidney care services provider to help expand access to Vafseo, or vadadustat, for patients on dialysis.Vafseo is indicated to treat anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, the company said.Under the multiyear contract, physicians will be able to prescribe Vafseo to patients on dialysis as deemed clinically appropriate. Akebia said it expects Vafseo to be available in the US in January 2025.The company's shares were up nearly 6% in recent trading.Price: 1.45, Change: +0.08, Percent Change: +5.84","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477351663"}